Literature DB >> 4332044

Susceptibility of recent isolates of Pseudomonas aeruginosa to gentamicin, polymyxin, and five penicillins, with observations on the pyocin and immunotypes of the strains.

J L Adler, M Finland.   

Abstract

The susceptibilities of recently isolated strains of Pseudomonas aeruginosa to gentamicin, polymyxin B, carbenicillin, ampicillin, penicillin G, and two newer penicillins were tested with the inocula-replicating technique by using undiluted and 10(-3) dilutions of the cultures. With either inoculum, polymyxin B was the most active agent, and a comparison with previous data from this laboratory showed that the susceptibility of P. aeruginosa to this antibiotic had not changed over the past 20 years. Gentamicin was nearly as active as polymyxin, all but 2 of the 141 strains tested with the diluted inoculum being inhibited by 6.25 mug/ml or less. AB-2288, an agent resembling carbenicillin, was four times more active than carbenicillin or BLP-1654; the last two were equally active against the 10(-3) inoculum. A more marked inoculum effect was noted with the penicillin analogues tested, the increase in minimum inhibiting concentration with the undiluted culture being eight-fold for carbenicillin and at least 16-fold for AB-2288 and BLP-1654. Pyocin typing and serotyping failed to demonstrate any clearly predominating types.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4332044      PMCID: PMC376437          DOI: 10.1128/am.22.5.870-875.1971

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  23 in total

1.  Susceptibility and crossresistance of bacteria to four related antibiotics: kanamycin, paromomycin, neomycin and streptomycin.

Authors:  C M KUNIN; C WILCOX; A NAJARIAN; M FINLAND
Journal:  Proc Soc Exp Biol Med       Date:  1958-11

2.  Occurrence of serious bacterial infections since introduction of antibacterial agents.

Authors:  M FINLAND; W F JONES; M W BARNES
Journal:  J Am Med Assoc       Date:  1959-08-29

3.  Observations on bacteriophage typing of Pseudomonas aeruginosa.

Authors:  B POSTIC; M FINLAND
Journal:  J Clin Invest       Date:  1961-11       Impact factor: 14.808

4.  Susceptibility of common pathogenic bacteria to seven tetracycline antibiotics in vitro.

Authors:  N H Steigbigel; C W Reed; M Finland
Journal:  Am J Med Sci       Date:  1968-03       Impact factor: 2.378

5.  Use of gentamicin in combinations with other antibiotics.

Authors:  C B Smith; P E Dans; J N Wilfert; M Finland
Journal:  J Infect Dis       Date:  1969 Apr-May       Impact factor: 5.226

6.  New immunotype schema for Pseudomonas aeruginosa based on protective antigens.

Authors:  M W Fisher; H B Devlin; F J Gnabasik
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

7.  Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy.

Authors:  J Koch-Weser; V W Sidel; E B Federman; P Kanarek; D C Finer; A E Eaton
Journal:  Ann Intern Med       Date:  1970-06       Impact factor: 25.391

8.  Further studies in the pyocine typing of Pseudomonas pyocyanea.

Authors:  J R Govan; R R Gillies
Journal:  J Med Microbiol       Date:  1969-02       Impact factor: 2.472

9.  Cephalosporinase and penicillinase activities of a beta-lactamase from Pseudomonas pyocyanea.

Authors:  L D Sabath; M Jago; E P Abraham
Journal:  Biochem J       Date:  1965-09       Impact factor: 3.857

10.  Carbenicillin: activity in vitro and absorption and excretion in normal young men.

Authors:  C B Smith; M Finland
Journal:  Appl Microbiol       Date:  1968-11
View more
  11 in total

1.  Antibiotic susceptibility testing of gram-negative nonfermentative bacilli.

Authors:  K A Ruddell; C R Anselmo
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

2.  Activity of three aminoglycosides and two penicillins against four species of gram-negative bacilli.

Authors:  R J Weinstein; L S Young; W L Hewitt
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

3.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

4.  Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.

Authors:  Jürgen B Bulitta; Jenny C Yang; Liliana Yohonn; Neang S Ly; Silvia V Brown; Rebecca E D'Hondt; William J Jusko; Alan Forrest; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2010-03-08       Impact factor: 5.191

5.  Bacteriocin typing by leakage of ultraviolet light-absorbing material.

Authors:  H Farkas-Himsley; A Pagel
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

6.  Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli.

Authors:  J E Rosenblatt; P R Stewart
Journal:  Antimicrob Agents Chemother       Date:  1974-07       Impact factor: 5.191

7.  Depression of contact sensitivity and enhancement of antibody response in Pseudomonas aeruginosa-infected mice.

Authors:  M Campa; C Garzelli; G Falcone
Journal:  Infect Immun       Date:  1975-12       Impact factor: 3.441

8.  Prevention of gram-negative bacillary pneumonia using aerosol polymyxin as prophylaxis. I. Effect on the colonization pattern of the upper respiratory tract of seriously ill patients.

Authors:  S Greenfield; D Teres; L S Bushnell; J Hedley-Whyte; D S Feingold
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

9.  Studies on the susceptibility of 150 consecutive clinical isolates of Pseudomonas aeruginosa to tobramycin, gentamicin, colistin, carbenicillin, and five other antimicrobials.

Authors:  W R Lockwood; L A Lawson
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

10.  The in vitro activity of ceftazidime against a multi-resistant serotype 12 Pseudomonas aeruginosa.

Authors:  G Ninane; P B Harper
Journal:  Infection       Date:  1983       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.